Form 4: CG Oncology Director Granted Stock Options Valued at $26.63 Per Share

CG Oncology, Inc. has granted 24,165 stock options to Director Hong Fang Song, with an exercise price of $26.63 per share, aligning executive incentives with shareholder value.

Summary

• Hong Fang Song, a Director at CG Oncology, Inc. (CGON), was granted 24,165 Director Stock Options.
• The options have an exercise price of $26.63 per share.
• The grant date for these options was June 5, 2025, and they expire on June 4, 2035.
• The vesting schedule for the options is 1/12th of the total shares vesting monthly following June 5, 2025.
• An accelerated vesting clause states that any remaining unvested portion will vest on the date of the next annual meeting of the Issuer's stockholders if it occurs prior to the first anniversary of the grant date.
• Vesting is contingent upon the Reporting Person's continuous service to the Issuer through each vesting date.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, which is generally viewed favorably. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation event.

Risks

• The value of the stock options is dependent on the future market price of CG Oncology's common stock; if the stock price does not exceed the exercise price of $26.63, the options may not be profitable.
• Vesting is subject to the director's continuous service, meaning the options could be forfeited if service is terminated before full vesting.

Future Outlook

The document primarily reports a past transaction (grant of options) and outlines the future vesting schedule and expiration date of these options. It does not provide broader forward-looking statements or guidance on company performance.

Management Comments

• The transaction was signed by Joshua F. Patterson, Attorney-in-Fact for Hong Fang Song.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for directors and executives, to incentivize long-term commitment and align their interests with company performance and shareholder returns. This is a standard compensation mechanism.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in high-growth sectors like biotechnology, to attract and retain talent and align interests.
• The vesting schedule (monthly over a period, with potential acceleration) is also a common structure designed to encourage continuous service and long-term commitment, comparable to practices at companies like Amgen or Gilead Sciences for their non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align their interests with shareholders, potentially leading to decisions that enhance long-term shareholder value. However, it also represents potential future dilution upon exercise.
• Employees: No direct impact mentioned for general employees, but it reflects the company's compensation philosophy for key personnel.

Next Steps

• The options will begin vesting monthly following June 5, 2025.
• The options will expire on June 4, 2035, if not exercised.

Key Dates

Keywords

CG Oncology, CGON, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Rule 10b5-1, Biotechnology, Oncology